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Background: Hemodynamic status and cardiac function are important factors for predicting pulmonary embolism
(PE) prognosis. Although inflammation is considered a risk factor for deep vein thrombosis, the prognostic
significance of both systemic inflammatory response syndrome (SIRS) and leukocytosis has not been elucidated.
This study evaluates PE prognostic factors, including SIRS and leukocytes.
Methods: This retrospective cohort study included 667 PE patients. Risk evaluation included SIRS and leukocytosis.
A prediction model was developed based on independent predictors of 30-day mortality.
Results: Fifty-seven patients (8.5%) died within 30 days of PE. Multivariate analysis showed that SIRS satisfying the
WBC criteria (odds ratio [OR], 2.8; 95% confidence interval [CI], 1.5–5.4), altered mental status (OR, 4.0; 95% CI, 1.8–
8.7), shock (OR, 2.6; 95% CI, 1.0-7.1), and right-to-left ventricle diameter ratio (OR, 1.7; 95% CI, 1.0-2.8) were associated
with 30-day mortality. SIRS criteria, including body temperature (OR, 4.6; 95% CI, 1.4–14.8), heart rate (OR, 2.0; 95%
CI, 1.1–3.6), respiratory rate (OR, 2.5; 95% CI, 1.4–4.6), and white blood cells (WBC) count (OR, 1.9; 95% CI, 1.2–3.5)
predicted short-term mortality following PE. The area under the receiver operating characteristic curve for the
prognostic model performance was 0.76 (95% CI, 0.66–0.85); pulmonary embolism severity index (PESI) and PESI +
WBC count were 0.72 (95% CI, 0.68–0.75) and 0.76 (95% CI, 0.72–0.79, P < 0.001 versus PESI), respectively.
Conclusions: Leukocytosis and SIRS are important factors in determining short-term outcomes in PE patients.
Keywords: Leukocytosis, Pulmonary embolism, Systemic inflammatory response syndromeBackground
Hemodynamic status and comorbidities are key factors
in the prognosis of pulmonary embolism (PE) [1,2]. In
addition to hemodynamic variables, cardiac biomarkers
such as troponins and natriuretic peptides are risk fac-
tors for patients with acute PE [3]. The PE prognostic
prediction model that is based on these variables is
widely accepted [2,4].
Initial risk stratification of patients with PE is based on
the presence of shock or hypotension [5]. If the patient
is hemodynamically stable, right ventricular function is
then assessed by echocardiography, and cardiac bio-
markers are measured [5]. However, these variables are* Correspondence: wichoi@dsmc.or.kr
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reproduction in any medium, provided the ornot accurate predictors of PE mortality, especially in
hemodynamically stable patients [6,7].
The triad of vessel wall injury, venous stasis, and blood
hypercoagulability has historically been considered a
major risk factor for venous thrombosis [8]. Infection is
another established risk factor for PE [9], and in certain
cases, PE has been associated with influenza [10] or
cytomegalovirus infection [11].
In deep vein thrombosis (DVT), an inflammatory reac-
tion triggers endothelial cell dysfunction [12,13] and re-
sults in high serum concentrations of the inflammatory
marker C-reactive protein [14]. Such inflammatory reac-
tions frequently induce well-studied DVT risk factors;
however, few studies have investigated a prognostic pre-
diction model for PE. Respiratory and pulse rates are in-
cluded in the representative PE severity index (PESI)
[15]. Nevertheless, there is a dearth of studies on theThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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response and PE patient prognosis.
Studies have suggested that leukocytes contribute to
venous thrombosis by damaging the endothelium
[16,17]. Animal models have shown that genetic knock-
out of the adhesion molecules E- and P-selectin results
in a reduction in thrombus size, which is associated with
altered leukocyte accumulation in the surrounding vein
wall [18]. However, the role of leukocytes in the progno-
sis of PE has not been well studied. We hypothesize that
both a systemic inflammatory response and leukocytosis
may be negative prognostic factors in PE patients.
Methods
Study design
This retrospective single center observational cohort
study was conducted between January 2005 and Decem-
ber 2011. This study was approved by the institutional
review board at Dongsan Hospital, Keimyung University
School of Medicine.
Study subjects
A total of 667 PE patients were enrolled at Dongsan
Hospital from January 2005 through December 2011. All
PE patients treated during the study period were in-
cluded; no additional selection criteria were used. Sub-
jects were either admitted to the hospital or were
Emergency Department or outpatient clinic patients.
Image studies
PE was defined either as a filling defect in the pulmonary
artery detected through chest computed tomography
(CT) or CT pulmonary angiography, or diagnosed based
on a ventilation perfusion scan. DVT diagnosis was con-
firmed via ultrasound examination of the lower extrem-
ity veins in patients with clinically suspected PE.
Study methods
Electronic medical records of all PE patients were exam-
ined. Risk factors included renal dysfunction, defined as
serum creatinine level >1.3 mg/dL; active cancer, defined
as treatment with an anti-cancer agent within 3 months
of PE diagnosis; hospital admission for supportive ther-
apy within 3 months of PE diagnosis; or outpatient use
of analgesics for end-stage malignancy. Shock was de-
fined as systolic blood pressure of <90 mmHg.
CT was performed using a 16 or 64-slice detector. The
reconstruction interval of the scan was 3 mm. The ratio
of right ventricular diameter to left ventricular diameter
(RV/LV ratio) was calculated using CT scan images
showing the interventricular septum and myocardium
from the longitudinal axis of the heart [19,20]. A radi-
ologist reviewed all the CT scans in a blind fashion.Patients were diagnosed with systemic inflammatory
response syndrome (SIRS) if they met 2 or more of the
following criteria: peripheral white blood cell (WBC)
count of <4,000/μL or >12,000/μL, respiratory rate >20
breaths per min, pulse rate >90 beats per min, and body
temperature of >38.3°C or <36.0°C [21]. We retrospect-
ively collected the clinical characteristics and laboratory
data on factors such as comorbidity, symptoms, chest
CT findings, vital signs, RV/LV ratio, NT Pro-BNP, and
complete blood count at the time of diagnosis of PE.
We defined 30-day all-cause mortality as a primary
outcome.
Statistical analysis
All values are expressed as mean ± standard deviation.
Data were analyzed using SAS version 9 (SAS Institute,
Cary, NC, USA) and MedCalc version 11.0 (MedCalc Soft-
ware, USA). A χ2 test was used to compare frequencies.
Student’s t test was used for statistical significance analysis
of continuous variables, and cross-analysis was used
for categorical variables. Statistical significance was set
at <0.05. Univariate analysis of statistically significant vari-
ables was conducted using logistic regression. Multivariate
analysis was performed for variables with a p-value
of <0.1. We used the area under the receiver operating
characteristic (ROC) curve or the area under the curve
(AUC) to quantify the ability of the model to distinguish
between high- and low-risk subjects. To compare the ROC
curves, we used the Delong et al. [22] method to calculate
the standard error of the AUC and the difference between
2 AUCs with the exact binomial confidence interval for the
AUCs. The improved discriminative and predictive values
of the WBC count + PESI score and the prognostic model
were examined by calculating the net reclassification im-
provement (NRI), as described by Pencina et al. [23].
Results
Of the 667 patients diagnosed with PE, 57 (8.5%) died
within 30 days of hospitalization, and 610 (91.5%) survived
at least 30 days after hospital admission (Table 1). All of
the patients were followed up 30 days after diagnosis of
PE. Causes of death were considered to be related to PE in
33 patients (58%); sepsis (n = 9); cancer (n = 7), major
bleeding (n = 4) and other causes (n = 4). PE was diag-
nosed using spiral chest CT in most patients (n = 635),
but was also diagnosed using lung ventilation/perfusion
scanning (n = 7), and based on DVT (n = 25). N-terminal
prohormone of brain natriuretic peptide (NT pro-BNP)
was measured in 322 patients. Complete blood count and
serum creatinine levels were measured in 663 patients.
Prognostic factors
No significant differences in age or sex were observed
between the group of patients who died within 30 days
Table 1 Clinical characteristics at diagnosis for the 667 patients
30-day all-cause mortality
Variable Overall (n = 667) No (n = 610) Yes (n = 57) P value
Age in years, mean (± SD) 66.4 (± 13.3) 66.9 (± 12.9) 67.8 (± 12.8) 0.60
Male, n (%) 295 (44.2%) 264 (43.2%) 31 (54.3%) 0.27
Comorbidity, n (%)
Heart failure 75 (11.2%) 64 (10.4%) 11 (19.2%) 0.19
Renal dysfunction 96 (14.3%) 79 (12.9%) 17 (29.8%) 0.001
Cancer 181 (27.1%) 161 (26.3%) 20 (35.0%) 0.15
Previous DVT or PE 49 (7.3%) 46 (7.5%) 3 (5.2%) 0.55
Infection 277 (41.5%) 243 (39.8%) 34 (59.6%) 0.006
Clinical finding, n (%)
Hemoptysis 17 (2.5%) 16 (2.6%) 1 (1.7%) 0.91
Chest pain 60 (8.9%) 58 (9.5%) 2 (3.5%) 0.57
Altered mental state* 65 (9.7%) 49 (8.0%) 16 (28.0%) <0.0001
Systolic blood pressure, mean (± SD), mmHg 121.8 (± 20.6) 123 (± 20.3) 110.5 (± 20.1) 0.0002
Shock† 36 (5.3%) 28 (4.5%) 8 (14.0%) 0.0025
Positive spiral CT, n (%)‡ 635 (95) 583 (95) 52 (91) –
Main pulmonary artery 247 (37) 220 (36) 27 (47) –
Lobar artery 235 (35) 218 (35) 17 (30) 0.429
Segmental artery 146 (22) 136 (22) 100 (17) –
Subsegmental artery 7 (1) 6 (1) 1 (2) –
Cardiac chamber ratio and cardiac biomarker, mean
RV/LV ratio (± SD) n = 635 1.22 (± 0.45) 1.20 (± 0.43) 1.51 (± 0.55) 0.0006
NT Pro-BNP, ng/L (± SD) n = 322 4906 (± 13381) 3637 (± 13523) 8917 (± 10861) 0.045
Systemic inflammatory response
Heart rate >90 beats/min 187 (28.0%) 157 (25.7%) 30 (52.6%) 0.0003
Respiratory rate >20 breaths/min 248 (37.1%) 212 (34.7%) 36 (63.1%) 0.001
Body temperature (BT) >38.3°C or <36.0°C, n (%) 15 (2.2%) 10 (1.6%) 5 (8.7%) 0.0005
WBC <4,000 or >12,000 mL, n (%) 196 (29.3%) 169 (27.7%) 27 (47.3%) 0.0018
SIRS≥ 2 191 (28.6%) 157 (25.7%) 34 (59.6%) <0.0001
SIRS Score (0–4) 0.29 (± 0.45) 0.27 (± 0.44) 0.52 (± 0.50) <0.0001
SIRS satisfying the WBC criteria, n (%) 113 (16.9%) 90 (14.7%) 23 (40.3%) <0.0001
PESI§ 95.9 (± 29.1) 93.3 (± 26.5) 122.9 (± 39.4) <0.0001
SD: standard deviation; DVT: deep vein thrombosis; PE: pulmonary embolism; NT pro-BNP: N-terminal prohormone of brain natriuretic peptide; RV: right ventricle;
LV: left ventricle; SIRS: systemic inflammatory response syndrome; WBC: white blood cell.
*Altered mental status was defined as disorientation, stupor, or coma.
†Shock was defined as systolic blood pressure < 90 mmHg.
‡Most proximal anatomic level of pulmonary embolism shown by spiral computed tomography.
§PESI: pulmonary embolism severity index [4].
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vived. We compared comorbidities identified at the time
of PE diagnosis, and found no significant differences be-
tween the 2 groups in terms of cardiac failure, active
cancer, or history of DVT or PE; renal dysfunction was
the only comorbidity in which a significant difference
was observed (Table 1).
We compared the clinical symptoms and vital signs of
the 2 groups, as recorded at the time of hospitalization.We found no significant inter-group differences in terms
of hemoptysis or chest pain; however, pulse rate (98.5 ±
25.2 versus 84.7 ± 14.2, P < 0.001), and respiratory rate
(25.3 ± 7.4 versus 21.4 ± 4.0, P < 0.001) were significantly
higher among the group of patients who died within
30 days of admission than that among the group of pa-
tients who survived for at least 30 days. Systolic blood
pressure was significantly lower in patients who died
(110.5 ± 20.1 versus 123 ± 20.3, P <0.001) than that
Table 2 Univariate and multivariate analyses of SIRS criteria
Univariate analysis Multivariate analysis
Variable OR (95% CI) P value OR (95% CI) P value
Body temperature >38.5°C or <36.0°C 5.7 (1.8–17.4) 0.002 4.6 (1.4–14.8) 0.008
Heart rate > 90 beats/min 3.2 (1.8–5.5) <0.001 2.0 (1.1–3.6) 0.019
Respiratory rate > 20 breaths/min 3.2 (1.8–5.6) <0.001 2.5 (1.4–4.6) 0.022
WBC <4,000 or >12,000 mL 2.3 (1.3–4.0) 0.023 1.9 (1.1–3.5) 0.018
SIRS: systemic inflammatory response syndrome; OR: odds ratio; bpm: beats per minute; WBC: white blood cell.
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ferences were also observed in terms of shock occur-
rence. N-terminal prohormone of brain natriuretic
peptide levels measured at the time of hospital admis-
sion, and the RV/LV ratios were significantly higher in
the group of patients who died within 30 days.
All SIRS criteria were significantly less common within
the survivor group (Table 1). Multivariate analysis
showed that all 4 SIRS criteria were significantly associ-
ated with mortality (Table 2). Univariate analysis of SIRS
satisfying the WBC criterion, RV/LV ratio, altered men-
tal state, renal dysfunction, infection, and shock identi-
fied all of these variables as statistically significant.
However, according to multivariate analysis, altered
mental state, shock, RV/LV ratio, and SIRS satisfying the
WBC criterion were statistically significant, while infec-
tion and renal dysfunction were not (Table 3). Based on
these variables, the AUC was calculated at 0.74 (95% CI,
0.64–0.83) (Figure 1).
Systemic inflammatory response satisfying the WBC
criteria as a prognostic factor of 30-day mortality of PE
patients
Three multivariate logistic regression models were devel-
oped: the first model was a clinical model that included
clinical variables; the second model was based on the
RV/LV ratio and laboratory variables; the final model
was based on SIRS (Table 2). In each model, alteredTable 3 Risk factors for 30-day mortality according to
multivariate analysis, model 1
Complete case analysis (n = 635)
Variable OR (95% CI) P value
Altered mental state† 4.0 (1.8–8.7) < 0.001
Infection 1.5 (0.8–2.9) 0.15
Cancer 1.7 (0.7-5.1) 0.18
Shock 2.6 (1.0–7.1) 0.04
Renal dysfunction 1.8 (0.8–4.0) 0.09
RV/LV ratio 1.7 (1.0–2.8) 0.04
SIRS satisfying WBC criterion 2.8 (1.5–5.4) 0.001
OR: odds ratio; RV: right ventricle; LV: left ventricle; SIRS: systemic
inflammatory response syndrome; WBC: white blood cell.
†Altered mental status was defined as disorientation, stupor, or coma.mental state, shock, active cancer, RV/LV ratio, and all
SIRS criteria were independently associated with 30-day
mortality. Furthermore, the association was statistically
significant for the RV/LV ratio and all the SIRS criteria.
According to the final multivariate model, altered mental
state, RV/LV ratio, and SIRS satisfying the WBC criter-
ion were independently associated with the 30-day mor-
tality of the 635 patients whose data were complete
(Table 3). The variables included in the model accounted
for 7.0% of the variation in individual 30-day mortality.
The final model had a strong predictive performance,
with an AUC of 0.76 (95% CI, 0.66–0.85) for all 635 pa-
tients (Figure 1). However, no statistically significant dif-
ference was observed between the ROC curves of the
different models. The internal validity of the predictive
model was checked by bootstrapping.
Patients were reclassified according to 30-day mortal-
ity based on the original clinical model and final model
adding RV/LV Ratio, renal dysfunction, SIRS satisfying
the WBC criterion (Table 4). For the 30-day non-
survivors, classification according to the final model was
more accurate for 20 patients and was not less accurate
for any patients, compared to classification according to
the clinical model. For the 30-day survivors, classifica-
tion according to the final model was more accurate for
17 patients and less accurate for 84 patients, compared
to classification according to the clinical model. The
NRI achieved by the final model was estimated at 24.0%
(P < 0.001).
Leukocytes as a prognostic factor of 30-day mortality
after PE
Both PESI scores and WBC counts were independently
associated with the 30-day mortality rate (Table 5). The
variables included in the model accounted for 11.8% of
the variation in individual 30-day mortality. The final
model had a strong predictive performance, with an AUC
of 0.76 (95% CI, 0.72–0.79) for all 654 patients studied
(Figure 2). There was a statistically significant difference
(P < 0.001) between the ROC curves of the PESI and the
PESI +WBC count models. The internal validity of the
predictive model was checked by bootstrapping.
Patients were reclassified according to 30-day mortal-
ity (Table 6); for the 30-day non-survivors, classification
Figure 1 Receiver operating characteristic curves for the 30-day mortality. The curves are based on logistic regression models for risk
prediction, incorporating the following: Model 1, shock on admission + altered mental state + active cancer (AUC = 0.64; 95% CI, 0.53–0.74); Model
1 + RV/LV ratio + renal dysfunction (AUC = 0.70; 95% CI, 0.59–0.76); Model 1 + RV/LV ratio + renal dysfunction + SIRS satisfying the WBC criterion
(AUC = 0.76; 95% CI, 0.66–0.85), P = 0.05 versus Model 1. AUC: area under the receiver operating characteristic curve; CI: confidence interval; RV:
right ventricle; LV: left ventricle; SIRS: systemic inflammatory response syndrome; WBC: white blood cell.
Table 4 Reclassification of patients according to 30-day
mortality based on the clinical model, RV/LV ratio, renal
dysfunction, and SIRS satisfying the WBC criterion
(Complete Case Analysis, n = 635)
Clinical model:
shock on admission +
altered mental
state + active cancer
Clinical model + RV/LV ratio + renal
dysfunction + SIRS satisfying the WBC criterion
<10% 10%–30% ≥30% Total
Non-survivors
<10% 20 15 0 35
10%–30% 0 11 5 16
≥30% 0 0 5 5
Total 20 26 10 56
Survivors
<10% 438 72 3 513
10%–30% 17 35 9 61
≥30% 0 0 5 5
Total 455 107 17 579
PE: pulmonary embolism; RV: right ventricle; LV: left ventricle; SIRS: systemic
inflammatory response syndrome; WBC: white blood cell.
Reclassification tables for survivors or non-survivors of PE were constructed
using PE risk categories [23], based on mortality prediction obtained by the
clinical model and the clinical model + RV/LV ratio + renal dysfunction + SIRS
satisfying WBC criterion, and included 3 categories: <10%, 10%–30%,
and ≥30% of 30-day mortality.
For the 56 non-survivors, classification improved using the model with RV/LV
ratio + renal dysfunction + SIRS satisfying the WBC criterion, but worsened for
20 subjects (cells in bold). For the 579 survivors, 17 subjects (cells in italics)
were reclassified down and 84 subjects (cells in bold) were reclassified up.
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curate for 4 patients and less accurate for 1 patient,
compared to classification according to PESI alone. For
the 30-day survivors, classification according to the final
model was more accurate for 35 patients and less accur-
ate for 18 patients, compared to classification according
to the clinical model. The NRI achieved by the final
model was estimated at 8.1% (P = 0.04). Thrombolytic
drugs, inferior vena cava filter, and surgical embolec-
tomy were used in 16, 7, and 2 of the cases, respectively.Discussion
The independent variables identified in this study as pre-
dictors of mortality within 30 days of hospital admission
for PE were: SIRS satisfying the peripheral blood WBC
count criterion, altered mental state, shock, and the RV/
LV ratio. In patients with PE, WBC count and SIRS sat-
isfying the peripheral WBC count criteria were signifi-
cantly associated with mortality within 30 days of
hospital admission (OR = 1.05, 95% CI, 1.01–1.09; OR =
2.8, 95% CI, 1.5–5.4, respectively) (Tables 2, 3).Table 5 Risk factors for 30-day mortality according to
multivariate analysis, model 2
Complete case analysis (n = 654)
Variable OR (95% CI) P value
PESI 1.03 (1.02–1.38) <0.01
WBC 1.05 (1.01–1.09) 0.01
PESI: pulmonary embolism severity index; OR: odds ratio; WBC: white
blood cell.
Figure 2 Receiver operating characteristic curves for the 30-day mortality. The curves are based on logistic regression models for risk
prediction, incorporating the following: Model 1, PESI (AUC = 0.72; 95% CI, 0.68–0.75); PESI + WBC count (AUC = 0.76; 95% CI, 0.72–0.79), P = 0.008
versus Model 1. PESI: pulmonary embolism severity index; AUC: area under the receiver operating characteristic curve; CI: confidence interval;
WBC: white blood cell.
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profiles, ranging from clinically stable to shock status.
Moreover, 30-day mortality rates in PE patients with
hemodynamic abnormalities have been reported to range
from 5% to 58% [1,24]. The prevalence of shock in our
sample was 5.3% (36 cases). The 30-day mortality rate
for PE patients presenting with shock was 25%. The RV/Table 6 Reclassification of 30-day survivors and
non-survivors based on PESI +WBC count (Complete Case
Analysis, n = 654)
PESI PESI +WBC count
<10% 10%–30% ≥30% Total
Non-survivors
<10% 26 3 0 29
10%–30% 0 15 1 16
≥30% 0 1 11 12
Total 26 19 12 57
Survivors
<10% 453 13 1 467
10%–30% 34 79 4 117
≥30% 0 1 12 13
Total 487 93 17 597
PESI: pulmonary embolism severity index; WBC: white blood cell.
Reclassification tables for survivors or non-survivors of PE were constructed
using PE risk categories [23], based on mortality prediction obtained by PESI +
WBC count. For the 57 non-survivors, classification improved using the model
with PESI + WBC count; 1 subject (cell in underline) was reclassified down and
4 subjects (cells in bold) were reclassified up. For the 579 survivors, 35 subjects
(cells in italics) were reclassified down and 18 subjects (cells in bold) were
reclassified up.LV ratio measured by chest CT indicated potential right
ventricular failure, which also reflects the severity of PE
[20]. The mean RV/LV ratio observed in the present
study was similar to that reported in a previous study
[19]. Moreover, the RV/LV ratio was significantly associ-
ated with 30-day mortality (OR = 1.7, 95% CI, 1.0–2.8),
which is consistent with previous reports that death
within 30 days of hospital admission is predictable [25].
However, the levels of N-terminal prohormone of brain
natriuretic peptide were not independently associated
with mortality our study. This may be, in part, due to
the limitations imposed on data collection, which are in-
herent to retrospective studies.
The percentage of PE patients with 3 or more risk fac-
tors, including infection, has been reported to be as high
as 50% [26]. This is expected, as WBCs are involved in
the coagulation process [27]. In the present study, we
demonstrated that in addition its role as a risk factor for
PE, SIRS also plays an important role in patient progno-
sis. Analysis of SIRS criteria showed that heart rate and
the WBC criterion were significantly associated with
mortality (Table 2). Multivariate analysis including all
significant variables, identified SIRS satisfying the WBC
count criterion as a significant prognostic factor
(Table 3). These results indicate that WBC count in the
systemic inflammatory response is an important prog-
nostic factor in PE patients. Although there was a sig-
nificantly higher percentage of infection in non-
survivors compared to survivors (Table 1), multivariate
analysis showed SIRS satisfying leukocytes criteria was
an independent predictor of outcome, while infection
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leukocytes criteria is a predictor of outcome, independ-
ent of coincident events such as an infection.
In contrast to studies that reported a significant asso-
ciation between the presence of a malignant tumor and
PE mortality [1,28], no such relationship was observed
in this study. We speculate that this lack of association
may be due to the recent progress in cancer management.
Indeed, this may also result in a difference in the ROC
curve from the original PESI [4]. Cancer survival rates are
currently improving [29-31], which may influence the re-
classification of the prognostic index in the future.
The area under the ROC curve of shock + altered men-
tal state + active cancer was 0.64, which is lower than the
previously reported value [28]. However, when RV/LV ra-
tio, renal dysfunction, and SIRS satisfying the WBC criter-
ion were included in the risk prediction model, a marginal
increase in the AUC from 0.64 to 0.76 (P = 0.05) was ob-
served. We classified the predicted risks obtained from
both models (old and new) into 3 categories (0%–10%,
10%–30%, >30% of 30-day PE mortality) and then cross-
tabulated these 2 classifications. Consequently, classifica-
tion was less accurate for approximately 36% of non-
survivors according to the new model, compared to the
old model. In contrast, classification was more accurate
for approximately 11% of survivors (Table 4).
The prognostic significance of WBC count was evalu-
ated using the previously established PE prognostic
index. Huang CM et al. also showed WBC count
(≥11,000 mm3) was an independent predictor of 30-day
mortality in PE patients [32]. Accordingly, we found that
WBC count was an independent prognostic factor, apart
from PESI, for 30-day PE mortality (Table 5). The area
under the ROC curve of PESI was 0.68, which is lower
than the previously reported value [4]. However, when
WBC count was added to the PESI, an increase in AUC
from 0.72 to 0.76 (P = 0.008) was observed. We classified
the predicted risks obtained from both models (PESI
and PESI +WBC) into 3 categories (0%–10%, 10%–
30%, >30% of 30-day PE mortality), and then cross-
tabulated these classifications. Consequently, the classifi-
cation of approximately 5% of non-survivors was less ac-
curate when comparing PESI +WBC with PESI alone.
Conversely, approximately 3% of survivors were reclassi-
fied down when WBC count was added to PESI (Table 6).
Thrombolytics, inferior vena cava filter, and surgical
embolectomy were performed in 16, 7, and 2 of the
cases included in this study, respectively. Thus, our ana-
lysis of prognostic factors did not account for treatment
method.
Conclusions
The independent prediction factors that demonstrated a
significant correlation with mortality within 30 days ofhospital admission were altered mental state at the time
of hospital admission, RV/LV ratio, SIRS satisfying the
WBC criterion, and WBC count. We suggest that careful
assessment of systemic inflammatory responses and
WBC count is necessary in determining the prognosis of
PE patients.
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